InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816626/0/en/InflaRx-Announces-Initiation-of-its-Commitment-Program-for-GOHIBIC-vilobelimab-to-Help-Broaden-Access-for-Eligible-Patients.html

ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) — InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit.

Read more at globenewswire.com

Related news for (IFRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.